Incyte Corporation (INCY)
Debt-to-equity ratio
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 5,189,840 | 4,370,120 | 3,770,000 | 2,611,270 | 2,598,410 |
Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $5,189,840K
= 0.00
The debt-to-equity ratio of Incyte Corp. has remained relatively stable over the past five years, ranging between 0.01 and 0.02. This suggests that the company has a conservative capital structure, with a low level of debt relative to its equity. A low debt-to-equity ratio indicates that the company is less reliant on borrowing to finance its operations, which can be seen as a positive sign of financial stability and lower financial risk. Overall, the consistent low levels of debt in relation to equity reflect a prudent financial management strategy by Incyte Corp.
Peer comparison
Dec 31, 2023
Company name
Symbol
Debt-to-equity ratio
Incyte Corporation
INCY
0.00
Arrowhead Pharmaceuticals Inc
ARWR
0.00
Charles River Laboratories
CRL
0.00
Exelixis Inc
EXEL
0.00
IQVIA Holdings Inc
IQV
2.12
Medpace Holdings Inc
MEDP
0.00